Bárbara Manuella Cardoso Sodré Alves

Bárbara Manuella Cardoso Sodré Alves

Auto-generated profile, based on publicly available information

Bárbara Manuella Cardoso Sodré Alves

Universidade de Brasília, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Revista da Sociedade Brasileira de Medicina Tropical
Verified
Journal Article
Open access
PDF file
BSBárbara Manuella Cardoso Sodré-Alves
Bárbara Manuella Cardoso Sodré-Alves
MTMelina Mafra Toledo
Melina Mafra Toledo
IZIvan Ricardo Zimmermann
Ivan Ricardo Zimmermann
Wildo AraujoWildo Araujo
Wildo Araujo
NTNoemia Urruth Leão Tavares
Noemia Urruth Leão Tavares
The treatment strategy for latent tuberculosis infection is to reduce the number of tuberculosis cases and consequently reduce the transmission of pathogenic bacteria. This study aimed to determine the safety, effectiveness, and adherence of isoniazid use for latent tuberculosis infection treatment.

1 November 2021 in Ciencia & Saude Coletiva
Verified
Journal Article
Open access
PLPollyanna Farias Castro Pereira de Lyra
Pollyanna Farias Castro Pereira de Lyra
DADyego Carlos Souza Anacleto de Araújo
Dyego Carlos Souza Anacleto de Araújo
GJGenival Araújo dos Santos Júnior
Genival Araújo dos Santos Júnior
BSBárbara Manuella Cardoso Sodré-Alves
Bárbara Manuella Cardoso Sodré-Alves
EJElisdete Maria Santos de Jesus
Elisdete Maria Santos de Jesus
LQLucindo Quintans-Junior
Lucindo Quintans-Junior
Patients without access to medicines often resort to the judicial system. However, no systematic review has discussed the quality of studies and the factors that may influence the access to medicines from judicialization. This study aimed to characterize the quality of research on access to judicialized medicines and their influence on public policies in Brazil. A search was conducted in the LILACS, PubMed/Medline, Scopus, and Web of Science databases using the terms “judicialization” and “medication”. Two reviewers identified articles that met the inclusion criteria. Only studies written in English, Portuguese, or Spanish published from 1990 to 2018 were included. The study selection resulted in a final sample of 45 articles. The retrospective descriptive design was the most common methods, based on reports and lawsuits. A high level of heterogeneity among the studies hindered the comparison and generation of evidence capable of supporting judges’ decisions based on technical-scientific criteria. This review showed that studies were heterogeneous and had low methodological quality. Moreover, they did not propose viable solutions for health managers and formulators to face the problem.

1 January 2024 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
RRRafael Cardinali Rodrigues
Rafael Cardinali Rodrigues
GGGabrielle Kéfrem Alves Gomes
Gabrielle Kéfrem Alves Gomes
BSBárbara Manuella Cardoso Sodré
Bárbara Manuella Cardoso Sodré
RLRodrigo Fonseca Lima
Rodrigo Fonseca Lima
DBDébora Santos Lula Barros
Débora Santos Lula Barros
DSDayde Lane Mendonça da Silva
Dayde Lane Mendonça da Silva
This study is a systematic literature review of the association between lists of potentially inappropriate medications (PIM) in clinical practice and health outcomes of older adults followed up in primary health care. For this purpose, the PRISMA protocol was used to systematize the search for articles in the PubMed, Web of Science, Scopus, Cochrane Central, LIVIVO and LILACS databases, in addition to the gray literature. Studies with randomized clinical trials were selected, using explicit criteria (lists) for the identification and management of PIM in prescriptions of older patients in primary care. Of the 2,400 articles found, six were used for data extraction. The interventions resulted in significant reductions in the number of PIM and adverse drug events and, consequently, in potentially inappropriate prescriptions (PIP) in polymedicated older adults. However, there were no significant effects of the interventions on negative clinical outcomes, such as emergency room visits, hospitalizations and death, or on improving the health status of the older adults. The use of PIM lists promotes adequate medication prescriptions for older adults in primary health care, but further studies are needed to determine the impact of reducing PIM on primary clinical outcomes.

22 March 2025 in Revista Brasileira de Medicina de Família e Comunidade
Verified
Journal Article
Open access
PDF file
LWLuane Michel Winck
Luane Michel Winck
MBMarcela Mofati Boechat
Marcela Mofati Boechat
BABárbara Manuella Cardoso Sodré Alves
Bárbara Manuella Cardoso Sodré Alves
DBDébora Santos Lula Barros
Débora Santos Lula Barros
RLRodrigo Fonseca Lima
Rodrigo Fonseca Lima
RSRafael Santos Santana
Rafael Santos Santana
Introduction: Cough is one of the main causes of demand for care in primary care, as it affects the patient’s quality of life. An acute cough is considered a self-limiting problem because it is of low severity and has a short latency period. Objective: The aim of this study was to evaluate the quality of clinical guidelines (CGs) for the treatment of acute cough. Methods: Searches were carried out on the websites of national and international institutions and organizations using the descriptors “cough,” “tos,” “practice guideline,” “guideline,” and “guide of clinical practice.” The selected guidelines were evaluated by four reviewers using the Appraisal of Guidelines for Research & Evaluation (AGREE II) instrument, and then, they were classified as strongly recommended, recommended with modifications, and non-recommended. Results: A total of 11 international guidelines were selected, published between 2006 and 2019, most from the United States of America. A total of seven guidelines were specific to the treatment of acute cough, only one guideline was focused on pharmaceutical care, and six were focused on the treatment of adults and children. Scope and purpose were the domains that presented the best score; editorial independence (D6) had the highest score variation (0–98%); and applicability (D5) of guidelines had the lowest mean score, 46% (range 2–88%). Regarding interventions, most of the guidelines referred to pharmacological interventions as unnecessary and the most cited non-pharmacological intervention was menthol (ointment). Conclusions: Therefore, it is necessary to carry out more clinical studies of good quality so that the CGs can be revised, to make the recommendations more reliable.

1 January 2024 in Epidemiologia e Serviços de Saúde
Verified
Journal Article
Open access
PDF file
JLJaqueline Costa Lima
Jaqueline Costa Lima
ÉGÉrica Marvila Garcia
Érica Marvila Garcia
SOSandra M.V.L. DE OLIVEIRA
Sandra M.V.L. DE OLIVEIRA
Wildo AraujoWildo Araujo
Wildo Araujo
ELEmmanuela Maria de Freitas Lopes
Emmanuela Maria de Freitas Lopes
VNValdir Nascimento
Valdir Nascimento
Objective To analyze full vaccination coverage in live births in 2017 and 2018 in the capitals of the Midwest region of Brazil, according to social strata. Methods Population-based household survey with cluster sampling. Full coverage in children at 12 and 24 months of age and sociodemographic factors were analyzed. Results 5,715 children were analyzed. Full coverage at 12 months of age was 67.9% (95%CI 65.4;70.4), while at 24 months it was 48.2% (95%CI 45.3;51.1). Pneumococcal vaccine had the highest vaccination coverage (91.3%), while the second dose of rotavirus vaccine had the lowest (74.2%). In Campo Grande, no vaccine reached coverage above 90%, with BCG (82.9%) and hepatitis B (82.1%) standing out. Campo Grande and Brasília had the worst vaccination coverage in the high social stratum (24 months of age). Conclusion Vaccination coverage in the Midwest was below 80%, falling short of the recommended target and associated with socioeconomic factors.

5 June 2023
Verified
Preprint
Open access
PDF file
BSBárbara Sodré-Alves
Bárbara Sodré-Alves
MTMelina Mafra Toledo
Melina Mafra Toledo
IZIvan R. Zimmermann
Ivan R. Zimmermann
WAWildo Navegantes de Araújo
Wildo Navegantes de Araújo
NTNoemia Urruth Leão Tavares
Noemia Urruth Leão Tavares
Background The treatment strategy for latent tuberculosis (TB) infection (LTBI) aims to promote a reduction in the number of cases that develop into TB and, consequently, a reduction in the transmission of pathogenic bacteria. Objectives The objective was to know the safety, effectiveness and adherence of the use of INH in two pharmaceutical presentations (300mg or 100mg tablet) reported in scientific studies. Methods A review protocol was registered a priori with PROSPERO (number CRD42020176694). The electronic databases Cochrane; PubMed; Embase; LILACS, Scopus, and Web of Science were searched for studies on use of INH for LTBI. The results and methods were presented in line with the PRISMA guidelines, and the methodological quality of the included reviews was assessed using the Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies. Results Most of the studies used isoniazid (H) as a treatment for LTBI, with a duration of 9 months. There was significant variation in the of use of isoniazid, ranging from 0.3% to 98.6% of the participants. A similar variation was found in the 52 studies that similarly presented the rate of adherence to treatment with H, which ranged from 18% to 100% among study participants completing INH treatment for LTBI. In studies, the adverse events reported most frequent events reported were included hepatotoxicity, gastric intolerance, and neuropathy, the rates of occurrence of these with isoniazid, rang from < 1% to 48%. In the studies that evaluated effectiveness of isoniazid for latent tuberculosis infection, a variation from 0 to 19.7% of people who did not have active TB after the follow-up period was observed, with the highest rate among HIV-positive individuals. Conclusion Our findings indicate that isoniazid is being widely used in the world as a prophylactic treatment for tuberculosis, rates of adherence to isoniazid were above 50%. It is important to emphasize the importance of keeping the follow-up of the person who uses isoniazid due to the risk of developing unwanted events resulting from the drug. Even with treatment challenges, we identified low rates of people who used isoniazid and developed active tuberculosis during the period they were followed. We believe that isoniazid continues to contribute to tuberculosis control in the world and better care actions are needed.